TY - JOUR
T1 - Overcoming Barriers in the Path to a Universal Influenza Virus Vaccine
AU - Coughlan, Lynda
AU - Palese, Peter
N1 - Funding Information:
We thank Dr. Florian Krammer for critical comments and review of this article. Supported in part by the National Institutes for Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) (P01AI097092, U19AI109946, and CEIRS contract HHSN272201400008C). L.C is funded by The HC Roscoe Grant 2016 from the British Medical Association Foundation for Medical Research.
Funding Information:
We thank Dr. Florian Krammer for critical comments and review of this article. Supported in part by the National Institutes for Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) ( P01AI097092 , U19AI109946 , and CEIRS contract HHSN272201400008C). L.C is funded by The HC Roscoe Grant 2016 from the British Medical Association Foundation for Medical Research .
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/7/11
Y1 - 2018/7/11
N2 - Influenza viruses are important pathogens which pose an ongoing threat to public health due to their ability to mutate and evade immunity elicited by prior infection or vaccination. Their evolutionary diversity is facilitated by the plasticity of the antigenically variable head domain of the major surface glycoprotein, hemagglutinin (HA), which tolerates the accumulation of extensive mutations. To date, vaccines have focused on eliciting largely strain-specific immune responses toward the HA head. However, novel universal influenza vaccines aim to refocus immunity toward the immunosubdominant but conserved influenza virus HA stalk domain. Such vaccines could provide heterologous protection against diverse influenza viruses.
AB - Influenza viruses are important pathogens which pose an ongoing threat to public health due to their ability to mutate and evade immunity elicited by prior infection or vaccination. Their evolutionary diversity is facilitated by the plasticity of the antigenically variable head domain of the major surface glycoprotein, hemagglutinin (HA), which tolerates the accumulation of extensive mutations. To date, vaccines have focused on eliciting largely strain-specific immune responses toward the HA head. However, novel universal influenza vaccines aim to refocus immunity toward the immunosubdominant but conserved influenza virus HA stalk domain. Such vaccines could provide heterologous protection against diverse influenza viruses.
UR - http://www.scopus.com/inward/record.url?scp=85049315230&partnerID=8YFLogxK
U2 - 10.1016/j.chom.2018.06.016
DO - 10.1016/j.chom.2018.06.016
M3 - Review article
C2 - 30001520
AN - SCOPUS:85049315230
SN - 1931-3128
VL - 24
SP - 18
EP - 24
JO - Cell Host and Microbe
JF - Cell Host and Microbe
IS - 1
ER -